An Open Label, Multicenter, Non-randomized, Active Controlled, Single Dose Escalation, Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of IN-105 under Fed Conditions in patients with Type 1 Diabetes Mellitus. - TIDM

Trial Profile

An Open Label, Multicenter, Non-randomized, Active Controlled, Single Dose Escalation, Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of IN-105 under Fed Conditions in patients with Type 1 Diabetes Mellitus. - TIDM

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Insulin lispro; Insulin tregopil
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 19 Aug 2010 Planned end date changed from 1 Jul 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 19 Aug 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 16 Jun 2010 New source identified and integrated (Clinical Trials Registry - India; CTRI2009-091-001008).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top